Loading
companiesCompany
CatalYm
CatalYm is a Germany-based biotechnology company running 5 late-stage cancer trials of Visugromab (CTL-002), Visugromab and visugromab (CTL-002) in non-small-cell lung cancer and hepatocellular carcinoma.
Also called: CatalYm GmbH
Overview
CatalYm, based in Planegg-Martinsried, Germany, is a biotechnology company. A private, venture-backed cancer immunotherapy company developing antibodies that neutralise GDF-15, a mechanism cancers use to resist treatment, with its lead candidate visugromab. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing Visugromab (CTL-002), Visugromab and visugromab (CTL-002) in non-small-cell lung cancer and hepatocellular carcinoma. The largest, NCT07112196 (Visugromab in Cachexia International Trial), plans to enrol 518 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Planegg-Martinsried, DE
Scorecard
All companies#368of 1244 companies, score 10
- phase 3 +3
- modalities +2
- registry trials +5
0 approved, 1 in phase 3, 0 earlier, 0 targets, 6 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Phase 3Anti-GDF-15 monoclonal antibody, intravenous
Visugromab is CatalYm's antibody against GDF-15, a tumour-made signal that both blocks immune cells and causes cancer wasting; it is in a phase 3 trial with PD-1 blockade after durable responses in patients whose cancers had stopped responding to checkpoint inhibitors.
cancers
drugs
Phase 3Anti-GDF-15 monoclonal antibody, intravenous
trials
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCTrial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLCVisugromab in Cachexia International TrialVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)